Latest Articles

Publication Date
Can Pembrolizumab Improve dMMR Endometrial Cancer Outcomes? - Medscape

Can Pembrolizumab Improve dMMR Endometrial Cancer Outcomes? Medscape

Published: Oct. 28, 2024, 1:14 p.m.
Casio to Release MR-G Inspired by the Brilliant Gleam of Japanese Katana Swords - bastillepost.com

Casio to Release MR-G Inspired by the Brilliant Gleam of Japanese Katana Swords bastillepost.com

Published: Oct. 24, 2024, 1 a.m.
Apolipoprotein-B mRNA-editing complex 3B could be a new potential therapeutic target in endometriosis - Nature.com

Apolipoprotein-B mRNA-editing complex 3B could be a new potential therapeutic target in endometriosis Nature.com

Published: Oct. 23, 2024, 4:55 a.m.
Markman’s Take: Vibostolimab in dMMR Endometrial Cancer, Adjuvant Chemo in Cervical Cancer, and More - OncLive

Markman’s Take: Vibostolimab in dMMR Endometrial Cancer, Adjuvant Chemo in Cervical Cancer, and More OncLive

Published: Oct. 21, 2024, 5:04 p.m.
Aditxt to Host a Virtual Fireside Chat with Aditxt CEO Amro Albanna and Evofem CEO Saundra Pelletier, Moderated by MD & Media Personality Dr. Drew Pinsky, on October 28, 2024, at 11:30 AM Eastern Time - StockTitan

Aditxt to Host a Virtual Fireside Chat with Aditxt CEO Amro Albanna and Evofem CEO Saundra Pelletier, Moderated by MD & Media Personality Dr. Drew Pinsky, on October 28, 2024, …

Published: Oct. 21, 2024, 12:15 p.m.
Endometriosis does not increase COVID-19 risk, worsen with mRNA vaccinations - Healio

Endometriosis does not increase COVID-19 risk, worsen with mRNA vaccinations Healio

Published: Oct. 14, 2024, 2:50 p.m.
Dostarlimab/Chemo Shows OS Benefit Regardless of MMR Status in Endometrial Cancer - OncLive

Dostarlimab/Chemo Shows OS Benefit Regardless of MMR Status in Endometrial Cancer OncLive

Published: July 3, 2024, 7 a.m.
Durvalumab Plus Olaparib Approaches EU Approval for pMMR Advanced or Recurrent Endometrial Cancer - OncLive

Durvalumab Plus Olaparib Approaches EU Approval for pMMR Advanced or Recurrent Endometrial Cancer OncLive

Published: July 1, 2024, 7 a.m.
Dr Bou Farhat on a Retrospective Study of NGS vs IHC Sensitivity for dMMR CRC and Endometrial Cancer - OncLive

Dr Bou Farhat on a Retrospective Study of NGS vs IHC Sensitivity for dMMR CRC and Endometrial Cancer OncLive

Published: May 21, 2024, 7 a.m.
Dr Porter on Mirvetuximab Soravtansine Plus Pembrolizumab in FRα+ pMMR/MSS Endometrial Cancer - OncLive

Dr Porter on Mirvetuximab Soravtansine Plus Pembrolizumab in FRα+ pMMR/MSS Endometrial Cancer OncLive

Published: April 8, 2024, 7 a.m.
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!